Clinical Trials Browser

Breast Neoplasms

NCT07008508 2025-06-06

BRAVE-Cyclin

Active not recruiting

300 enrolled

BreastClassical hematology

Breast Neoplasms, Cardiovascular Diseases, Venous Thromboembolism

NCT06805812 2025-02-03

PALMARES-2

Recruiting

3,500 enrolled

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT06525675 2024-12-13

Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

Completed

419 enrolled

Breast

Breast Neoplasms

NCT06607601 2024-09-23

CARE Initiative: Real-world Emulation of the PALOMA-2 Trial

Completed

724 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT06367335 2024-04-16

ETIC

Completed

128 enrolled

DILI

NCT06338644 2024-03-29

Palbociclib

Not yet recruiting

100 enrolled

Breast

Breast Neoplasms

NCT06076772 2023-10-11

Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients

Not yet recruiting

54 enrolled

Breast

Breast Neoplasms

NCT05135104 2023-05-17

PALBO

Unknown

650 enrolled

Breast

Breast Neoplasms

NCT03285568 2023-03-31

Patterns of Prescribing and Monitoring of Palbociclib

Completed

67 enrolled

Breast

Breast Neoplasms

NCT04874025 2022-08-08

PALBOSPAIN

Completed

815 enrolled

Breast

Breast Neoplasms

NCT04992156 2022-05-19

Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET

Completed

50 enrolled

Breast

Breast Neoplasms

NCT05051956 2021-09-21

Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?

Unknown

140 enrolled

Breast

Can the Geriatric Questionnaires Predict Adverse Effects in Geriatric Breast Cancer Patients Treated With Cyclin-dependent Kinase 4 and 6 Inhibitors

NCT04852081 2021-04-21

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Unknown

1,000 enrolled

Breast

Breast Neoplasms

NCT04526028 2020-08-25

Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

Unknown

612 enrolled

Breast

Breast Neoplasms

NCT04524728 2020-08-24

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

Completed

191 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT04109261 2019-09-30

PALBOCOMP

Completed

237 enrolled

Breast

Breast Neoplasms

Clinical Trials

PALLAS-IRAQ

BRAVE-Cyclin

PALMARES-2

Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

CARE Initiative: Real-world Emulation of the PALOMA-2 Trial

ETIC

Palbociclib

Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients

PALBO

Patterns of Prescribing and Monitoring of Palbociclib

PALBOSPAIN

Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET

Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

PALBOCOMP